Trial Profile
A Phase 1/2 Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO - 204)
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 28 Apr 2023
Price :
$35
*
At a glance
- Drugs Epacadostat (Primary) ; Nivolumab (Primary)
- Indications Adenocarcinoma; Carcinoma; Colorectal cancer; Diffuse large B cell lymphoma; Glioblastoma; Head and neck cancer; Hodgkin's disease; Malignant melanoma; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Ovarian cancer; Solid tumours; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms ECHO-204
- Sponsors Bristol-Myers Squibb; Incyte Corporation
- 26 Aug 2020 Status changed from active, no longer recruiting to completed.
- 04 Mar 2020 Planned primary completion date changed from 1 Apr 2020 to 18 Jul 2020.
- 09 Jul 2019 Planned End Date changed from 1 Oct 2020 to 18 Jul 2020.